Kestra Medical Technologies
Kestra Medical Technologies' revenue rose 59.0% to $95 million in fiscal 2026. Its operating margin was −141.6%, up from −177.8% a year earlier. Free cash flow was −$117 million. The diluted share count rose 120.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Kestra Medical Technologies does
Kestra Medical Technologies makes a wearable heart device for people at risk of sudden cardiac arrest, when the heart suddenly stops pumping. Its ASSURE wearable cardioverter defibrillator watches the wearer's heart rhythm all the time and gives an electric shock on its own if it detects a dangerous rhythm. The US Food and Drug Administration approved it in July 2021 for adults at elevated risk who cannot have, or decline, an implanted defibrillator.
Doctors prescribe it for patients in a recovery period, for example after a heart attack or a new diagnosis of a weak heart muscle, when an implanted device is not yet an option. Most patients are prescribed it for three months or longer. The device is part of what Kestra calls its Cardiac Recovery System, which adds digital tools for patient engagement and for doctors to track patients. Kestra says its device had protected nearly 40,000 patients since launch as of April 30, 2026.
Kestra earns most of its revenue by leasing the ASSURE device, and it is paid by Medicare and private insurers. It sells only in the United States and has no approvals elsewhere. It competes with other makers of wearable defibrillators. It has a history of net losses and a limited operating history.
Its biggest risks, as it describes them
- Depending on one product, the ASSURE device, for nearly all its revenue.
- Insurers and government programs not covering or paying enough for its device, and complex billing.
- A history of net losses and a limited operating history.
- Relying on a limited number of outside suppliers and contract manufacturers.
- Doctors, hospitals and patients not adopting the device, or competitors winning more acceptance.
Income statement
Kestra Medical Technologies lost money in fiscal 2026: a net loss of $132 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | 8 | 238 | 262 |
| Debt incl. finance leases | 42 | 41 | 43 |
| Net debt (negative means net cash) | 34 | −196 | −220 |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | 0.2x | 0.2x |
| Interest coverage | −13.7x | −13.8x | −17.9x |
| Current ratio | 0.5x | 6.7x | 4.4x |
| Quick ratio | 0.5x | 6.7x | 4.4x |
Cash flow
Projections
Project Kestra Medical Technologies' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Kestra Medical Technologies reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY25 | FY26 |
|---|---|---|
| Piotroski F-score | — | 4 of 9 |
| Rule of 40 | −53.0% | −63.5% |
| Altman Z'' | −0.94 | −2.55 |
| Accruals ratio | −21.2% | −15.3% |
The nine F-score tests
| Test | FY25 | FY26 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | Pass |
| Current ratio rose | Pass | Fail |
| Share count didn't rise | Fail | Fail |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | Fail |
| F-score | — | 4 of 9 |
Compare
Put Kestra Medical Technologies side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Kestra Medical Technologies | FY26 | 59.0% | −141.6% | −122.6% | — | — | 4 | |
| Butterfly Network | FY25 | 19.0% | −88.5% | −16.4% | — | — | — | Compare |
| Beta Bionics | FY25 | 53.9% | −71.5% | −56.1% | — | — | — | Compare |
| Ceribell | FY25 | 36.1% | −65.6% | −46.7% | — | — | — | Compare |
| Delcath Systems | FY25 | 129.1% | 0.8% | 24.6% | 2.8% | −101.4x | 6 | Compare |
3 years of figures
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | 28 | 60 | 95 |
| Revenue growth | — | 115.0% | 59.0% |
| Gross profit | 0 | 24 | 49 |
| Research and development | 16 | 16 | 20 |
| Operating income | −85 | −106 | −135 |
| Net income | −94 | −114 | −132 |
| Diluted EPS (US$) | −5.07 | −5.13 | −2.43 |
| Diluted shares (millions) | 20 | 25 | 54 |
| Cash flow | |||
| Cash from operations | −72 | −78 | −82 |
| Capital expenditure | 12 | 23 | 35 |
| Free cash flow | −84 | −101 | −117 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 2 | 24 | 34 |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 8 | 238 | 262 |
| Debt incl. finance leases | 42 | 41 | 43 |
| Total assets | 46 | 296 | 358 |
| Total liabilities | 78 | 90 | 99 |
| Shareholders' equity | −209 | 205 | 260 |
| Margins and ratios | |||
| Gross margin | 1.3% | 40.5% | 51.4% |
| Operating margin | −305.8% | −177.8% | −141.6% |
| Net margin | −338.4% | −190.3% | −138.4% |
| Free cash flow margin | −303.7% | −168.1% | −122.6% |
| Rule of 40 (growth + FCF margin) | — | −53.0% | −63.5% |
| Return on capital | — | — | — |
| Return on equity | — | — | −56.6% |
| Return on assets | — | −66.6% | −40.2% |
| Net debt to EBITDA | — | — | — |